Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

How and When the Memory Chip Shortage Will End

View original at spectrum.ieee.org
IEEE Spectrum - Technical Title: How and When the Memory Chip Shortage Will End Date: 2026-02-10 14:00 Source: https://spectrum.ieee.org/dram-shortage <img src="https://spectrum.ieee.org/media-library/sk-hynix-inc-s-12-layer-hbm4-memory-chips-on-display.jpg?id=63918122&width=1245&height=700&coordinates=0%2C187%2C0%2C18…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • HBM generally costs three times as much as other types of memory and constitutes 50 percent or more of the cost of the packaged GPU.

    80% confidence
  • Relief will come from a combination of incremental capacity expansions by existing DRAM leaders, yield improvements in advanced packaging, and a broader diversification of supply chains. New fabs will help at the margin, but the faster gains will come from process learning, better DRAM stacking efficiency, and tighter coordination between memory suppliers and AI chip designers.

    80% confidence
  • There are two ways to address supply issues with DRAM: with innovation or with building more fabs. As DRAM scaling has become more difficult, the industry has turned to advanced packaging, which is just using more DRAM.

    80% confidence
  • DRAM is a highly cyclical industry with huge booms and devastating busts. With new fabs costing $15 billion or more, firms are extremely reluctant to expand and may only have the cash to do so during boom times. Building a fab and getting it up and running can take 18 months or more, practically ensuring that new capacity arrives well past the initial surge in demand.

    80% confidence
  • Micron predicts the total market for HBM will grow from $35 billion in 2025 to $100 billion by 2028, a figure larger than the entire DRAM market in 2024, reached two years earlier than previously expected. Demand will outstrip supply substantially for the foreseeable future.

    80% confidence
  • There are nearly 2,000 new data centers either planned or under construction globally, representing a potential 20 percent jump in global supply from the current approximately 9,000 facilities.

    80% confidence
  • DRAM prices have risen 80-90 percent so far this quarter (Q1 2026).

    80% confidence
  • After a recovery began in late 2023, all the memory and storage companies were very wary of increasing their production capacity again, resulting in little or no investment in new production capacity in 2024 and through most of 2025.

    80% confidence
  • There will be no relief in the DRAM market until 2028.

    80% confidence
  • The origins of today's DRAM cycle go back to the chip supply panic surrounding COVID-19. Hyperscalers bought up huge inventories of memory and storage to avoid supply-chain stumbles and support the rapid shift to remote work, boosting prices.

    80% confidence
  • Companies will spend $7 trillion on data centers by 2030, with $5.2 trillion going to AI-focused data centers, of which $3.3 billion will go toward servers, data storage, and network equipment.

    80% confidence
  • In general, economists find that prices come down much more slowly and reluctantly than they go up. DRAM today is unlikely to be an exception, especially given the insatiable demand for compute.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com